Remnant Gastric Cancer: Neglect Group with High Potential for Immunotherapy

The importance of targeted therapy for gastric cancer (GC) has increased in recent years with anti-HER2 therapy and immunotherapy for microsatellite instability (MSI) and PD-L1+ tumors. However, most of the trials does not include remnant GC (RGC), so the potential for target therapy in these patients remains unknow. Our objetive was to evaluate the clinicopathological characteristics of RGC and its association with the expression of current markers for target therapy.

Source: Journal of the American College of Surgeons - September 30, 2020 Category: Surgery Authors: Marcus Fernando Kodama P. Ramos, Marina Alessandra Pereira, Tiago Biachi Castria, Renan Ribeiro e Ribeiro, Evandro Sobroza Mello, Andre Roncon Dias, Bruno ZIlberstein, Ulysses Ribeiro, Ivan Cecconello Tags: Surgical Oncology Source Type: research